YPrime, LLC, announced today the strategic acquisition of Tryl, a software development company with a unique patient engagement solution that brings together beautiful design, dynamic personalization, and applied behavioral science that is designed to boost engagement, reduce dropouts, and deliver outcomes in clinical trials.
| MALVERN, Pa., Feb. 8, 2022 /PRNewswire/ -- YPrime, LLC, a global leader in cloud-based eClinical solutions, announced today the strategic acquisition of Tryl, a software development company with a unique patient engagement solution that brings together beautiful design, dynamic personalization, and applied behavioral science that is designed to boost engagement, reduce dropouts, and deliver outcomes in clinical trials. The acquisition includes the transfer of all staff, development capabilities, and intellectual properties to YPrime, and will integrate with YPrime’s Patient Engagement Technologies solutions. “YPrime’s major priority has always been to anticipate the needs of tomorrow’s clinical trials and create powerful eClinical tools that simplify the lives of sponsors, sites, and patients,” says Shawn Blackburn, CEO, YPrime. “This combination with Tryl helps us leap ahead in fulfilling our vision of creating the industry’s first-of-its-kind solution to help keep patients more informed and engaged throughout the entire clinical trial process, especially as our industry accelerates toward decentralized clinical trial models.” “An ever-increasing focus on patient centricity demands an integrated approach to how patients are engaged,” says Ian Greenfield, CEO of Tryl. “This starts from the moment patients are recruited and continues throughout the entire patient journey. YPrime has a strong vision for the future and by bringing together offerings from our two companies, we can create a novel solution that takes head on the most pressing challenges associated with attracting, engaging, and retaining patients.” Tryl’s tools provide an experience that is personalized, predictive, empathetic, and relative to the overall patient journey. Tryl’s proprietary engagement score is designed to reduce patient dropout rates. Rooted in consumer experience, the Tryl team applies proven behavioral principles from other industries (such as professional sports and consumer finance) to seek to improve patient adherence to study protocols. Mark Maietta, President, YPrime expressed his enthusiasm, “The addition of the Tryl team and their innovative solutions will boost patient compliance and reduce attrition, and the timing is perfect. YPrime has built an enviable market position with its strong eCOA and IRT capabilities. Now we can seamlessly layer on complementary solutions to our innovative technology stack for running successful decentralized trials.” About YPrime About Tryl CONTACT:
SOURCE YPrime, LLC |
View original content:
